Alternatives to ANI

Diversified biopharmaceutical company focused on rare diseases, generics, and established brands.

Biopharmaceutical company developing therapies for neurodegenerative diseases, focusing on crossing the blood-brain barrier.

Epicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).

Developing human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.

Clinical-stage biopharmaceutical company leveraging a proprietary platform to discover and develop novel precision medicines from fungi.

Biopharmaceutical company developing novel small-molecule therapeutics for rare kidney diseases, particularly Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Israeli-UK biotech company developing novel RNA therapeutics for rare genetic diseases.

Developing novel therapeutics for rare genetic diseases with a focus on protein degradation.

Clinical-stage biotechnology company developing Antibody Oligonucleotide Conjugates (AOCs) for serious diseases.

Biopharmaceutical company developing innovative punctal plug technology for eye disease therapies.

Global biopharmaceutical company specializing in plasma-derived therapeutics for rare and serious conditions.

A clinical-stage biotechnology company developing transformative genome editing medicines for serious diseases.

Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.

Developing novel therapeutics for rare and underserved diseases.

Mapping and reprogramming the immune system with single-cell biology and AI for therapeutic discovery.

Global biopharmaceutical company pioneering mRNA-based immunotherapies and vaccines for cancer and infectious diseases.

Global CRDMO providing integrated R&D and manufacturing services for the pharmaceutical and life sciences industries.

AI-driven digital twin of embryo development for cell-based therapies.

AI-guided drug discovery platform for tissue-targeted medicines.

Developing microbiome-derived therapies to overcome resistance to immune checkpoint inhibitors in cancer treatment.